• Alamar Biosciences flagged a Lancet Neurology publication on a longitudinal real-world study tracking plasma biomarkers during lecanemab treatment.
• Results were presented as published findings, not a future conference readout.
• Study conclusion: amyloid clearance signals diverged from markers tied to later cognitive decline, suggesting treatment effects do not align with clinical response.
• Biomarker shifts varied across patients during dosing, indicating heterogeneous biological responses that could affect how therapy is monitored in practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241851PRIMZONEFULLFEED9833783) on September 24, 2026, and is solely responsible for the information contained therein.